AstraZeneca PLC (AZNCF)

OTCMKTS · Delayed Price · Currency is USD
167.00
-2.12 (-1.25%)
Oct 17, 2025, 4:00 PM EDT
-1.25%
Market Cap260.83B
Revenue (ttm)56.50B
Net Income (ttm)8.30B
Shares Outn/a
EPS (ttm)5.31
PE Ratio31.44
Forward PE17.26
Dividend3.13 (1.83%)
Ex-Dividend DateAug 7, 2025
Volume1,000
Average Volume3,627
Open167.00
Previous Close169.12
Day's Range167.00 - 167.00
52-Week Range120.64 - 175.00
Beta0.17
RSI63.30
Earnings DateNov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange OTCMKTS
Ticker Symbol AZNCF
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial Statements

News

AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat for...

1 day ago - Reuters

AstraZeneca : ENHERTU Shows Significant Survival Benefit In DESTINY-Breast05 Phase III Trial

(RTTNews) - AstraZeneca announced that the Phase III DESTINY-Breast05 trial demonstrated ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improves invasive disease-free survival (IDFS) in patie...

1 day ago - Nasdaq

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials

1 day ago - GuruFocus

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

2 days ago - Reuters

AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash

AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.

2 days ago - Investor's Business Daily

Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation

(RTTNews) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment for inadequately control...

2 days ago - Nasdaq

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $84.69, marking a +1.03% move from the previous day.

2 days ago - Nasdaq

AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis

AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis

2 days ago - GuruFocus

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen's TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years ...

2 days ago - Business Wire

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.

2 days ago - Reuters

AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects

AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects

2 days ago - GuruFocus

Astra, GSK up after report on U.K. – U.S. drug pricing deal

AstraZeneca (AZN) stock and GSK (GSK) stock gain as the U.K. and U.S. are reportedly clining in on a major drug pricing deal. Read more here.

2 days ago - Seeking Alpha

AstraZeneca (AZN) Gains EU Backing for New Lupus Treatment

AstraZeneca (AZN) Gains EU Backing for New Lupus Treatment

2 days ago - GuruFocus

AstraZeneca's Imfinzi Improves Disease-Free Survival In Early-Stage Bladder Cancer

(RTTNews) - AstraZeneca (AZN), Friday announced positive Phase III results from its POTOMAC trial, showing that adding one year of treatment with Imfinzi; durvalumab to standard BCG therapy significan...

3 days ago - Nasdaq

SPDW, ASML, SAP, AZN: ETF Inflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...

3 days ago - Nasdaq

AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI

AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI

3 days ago - GuruFocus

AstraZeneca's (AZN) IMFINZI Shows Promising Results in Bladder Cancer Trial

AstraZeneca's (AZN) IMFINZI Shows Promising Results in Bladder Cancer Trial

3 days ago - GuruFocus

AstraZeneca (AZN) Lung Cancer Trial Highlights New Diagnostic Tool

AstraZeneca (AZN) Lung Cancer Trial Highlights New Diagnostic Tool

4 days ago - GuruFocus

AstraZeneca (AZN): Lynparza's Role in Ovarian Cancer Treatment

AstraZeneca (AZN): Lynparza's Role in Ovarian Cancer Treatment

4 days ago - GuruFocus

AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Production

AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Production

5 days ago - GuruFocus

AstraZeneca unveils expanded manufacturing facility in Texas

COPPELL, Texas--(BUSINESS WIRE)--AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the produ...

5 days ago - Business Wire

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...

5 days ago - Benzinga

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve

AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.

6 days ago - Nasdaq